

Financial Tear Sheet

Corporate Profile

Iovance Biotherapeutics (formerly traded as Lion Biotechnologies) is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). This approach, also known as adoptive T-cell therapy, was developed by Dr. Steven A. Rosenberg at the National Cancer Institute. In Phase 2 clinical trials conducted at the NCI, 56% and 24% of patients treated with this technology achieved objective and complete response criteria, respectively.

Our lead product candidate is an autologous, ready-to-infuse cell therapy, that has demonstrated distinctive efficacy in the treatment of metastatic melanoma.

In addition to metastatic malignant melanoma, carcinoma of the head and neck and cervical cancer our TIL therapy technology is potentially applicable to many other tumor types, including ovarian, breast, bladder, colorectal and other cancers. As we continue advancing our current clinical programs through the introduction of manufacturing and logistical efficiencies aimed at decreasing production time and optimizing distribution processes, we aim to establish TIL therapy as a revolutionary, accessible, mainline cancer therapy.

Primary IR Contact

Stern Investor Relations, Inc.

Sarah McCabe

Phone: 212-362-1200

E-mail:

sarah@sternir.com

Stock Performance

IOVA (Common Stock)

Exchange NASDAQ (US Dollar)

Price **\$4.70**

Change (%) **▲ 0.05 (1.08%)**

Volume 223,569

52 Week High \$9.44

52 Week Low \$4.45

Market Cap \$294,626,715

Rolling EPS -2.11

PE Ratio 0

Shares Outstanding 62,686,535

Data as of August 18, 2017 4:00 p.m. ET



Recent Headlines

August 16, 2017

[Iovance Biotherapeutics Announces First Patient Dosed in C-145-04 Phase 2 Trial in Cervical Cancer](#)

August 8, 2017

[Iovance Biotherapeutics Appoints Timothy Morris as Chief Financial Officer](#)

August 1, 2017

[Iovance Biotherapeutics Reports Second Quarter 2017 Financial Results](#)

SEC Filings

Filing Date	Form
August 16, 2017	4
August 16, 2017	3
August 8, 2017	8-K
August 3, 2017	EFFECT

Data provided by Nasdaq. Minimum 15 minutes delayed.

Upcoming Events

Date	Title
September 12, 2017 5:05 p.m. ET	Rodman & Renshaw 19th Annual Global Investment Conference
September 25, 2017 8:00 a.m. ET	2017 Cantor Fitzgerald Global Healthcare Conference

Corporate Governance

© 2017 Lion Biotechnologies, Inc. All Rights Reserved.